| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T314 |
0-88 |
Sentence |
denotes |
Genetically modified NK cells are also being investigated for efficacy against COVID-19. |
| T315 |
89-440 |
Sentence |
denotes |
Chimeric antigen receptor NK cells (CAR-NK cells) are engineered to express virtually any receptor(s) of interest and were originally designed to enhance the ability of NK cells to eliminate cancer cells via receptors targeting EGFR (163) or CD19 (164), which are present on many cancer types and B cell hematological malignancies, respectively (164). |
| T316 |
441-758 |
Sentence |
denotes |
Although the efficacy of CAR-NK cells to control viral infections has yet to be rigorously tested in large scale clinical trials, the promising safety profile of CAR-NK cells in cancer patients, who are often immunocompromised, suggests that CAR-NK therapy can be well-tolerated in early phase/mild COVID-19 patients. |
| T317 |
759-935 |
Sentence |
denotes |
Notably, CAR-NK cells are considered “safe” largely because they are less likely to lead to cytokine release syndrome (CRS), a severe adverse event of CAR-T cell therapy (165). |
| T318 |
936-1073 |
Sentence |
denotes |
But as these are unchartered waters, it is critical that CAR-NK cells are used cautiously and not given to late/severe COVID-19 patients. |
